Bli medlem
Bli medlem

Du är här


AroCell: Final call for trading with BTA

During the month of December 2015 AroCell AB (publ) conducted a
preferential rights issue. The last day for trading with BTA will
take place on January 12th 2016 and the stop day is January 14th
2016. BTA's will be converted to shares January 18th 2016.

After the preferential rights issue the share capital will be 2 867
450,60 SEK distributed on 28 674 506 shares.

Redeye AB is the financial advisor for the preferential rights issue
in collaboration with Corpura AB. Legal advisor is Fredersen
Advokatbyrå AB.

For more information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706-926206

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern
blood tests to support the prognosis and follow up of cancer
patients. AroCell's new technology is based on patented methods to
measure TK1 protein levels, which provide valuable information about
the speed of cell turnover. A tumor has high cell turnover (speed of
cell division and cell death) and as a result TK1 can be detected in
the blood with a simple laboratory test, called TK 210 ELISA. The
test provides valuable clinical information for prognosis and
optimization of treatment strategy. The test may also be used for
monitoring disease relapse. For more information, please see . AroCell AB (AROC) is listed at AktieTorget and has
about 2 300 shareholders.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.